ABSTRACT We present here the first draft genome sequence of Leishmania (Viannia) lainsoni strain 216-34, sequenced using PacBio and MiSeq platforms. PacBio contigs were generated from de novo assemblies using CANU version 1.6 and polished using Illumina reads. Treatment is recommended for most cases of CL. However, the drugs typically used for treating CL are associated with several adverse side effects. In addition, the choice of therapeutic agents and their efficacy vary by clinical characteristics and parasite-specific factors (3-5). Therefore, DNA-based diagnostic tests that allow specific identification of infecting parasite species are critical for appropriate clinical management, including decisions regarding which treatment is indicated and how to monitor for relapse and sequelae.
) peruviana, are associated only with CL. Treatment is recommended for most cases of CL. However, the drugs typically used for treating CL are associated with several adverse side effects. In addition, the choice of therapeutic agents and their efficacy vary by clinical characteristics and parasite-specific factors (3) (4) (5) . Therefore, DNA-based diagnostic tests that allow specific identification of infecting parasite species are critical for appropriate clinical management, including decisions regarding which treatment is indicated and how to monitor for relapse and sequelae.
As a part of our efforts to improve the quality of species-specific diagnostics for leishmaniasis, we present here the first draft genome sequence of L. (V.) lainsoni, that of strain 216-34, derived from a parasite isolated in our laboratory from a clinical case from Peru in 2016. Parasites grown in RPMI 1640 axenic medium (Life Technologies, CA) were initially identified on the basis of morphological analysis (6) . Later, the species identity of L. (V.) lainsoni was confirmed using multilocus sequence analysis (MLSA) targeting glucose-6-phosphate dehydrogenase (G6PDH), isocitrate dehydrogenase (ICD), malate dehydrogenase (MDH), and mannose-6-phosphate isomerase (MPI) Leishmania sp. enzyme-coding genes. The sequencing data, generated on an ABI 3130xl DNA analyzer (Applied Biosystems, CA), were compared with the NCBI nucleotide database using the BLASTn algorithm (https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE _TYPEϭBlastSearch).
MiSeq and PacBio libraries were prepared with genomic DNA purified using the MagAttract high-molecular-weight (HMW) DNA kit (Qiagen, MD). For the short reads, libraries were prepared with NEBNext Ultra library prep reagents (New England BioLabs, MA), barcoded with indices produced at the CDC Biotechnology Core Facility, and sequenced using a MiSeq 2 ϫ 250-cycle sequencing kit (Illumina, CA). Sequence reads were filtered for read quality, base called, and demultiplexed using bcl2fastq (version 2.19). Long-read sequencing data were obtained from a 20-kb DNA library and pre-pared using standard PacBio 20-kb library protocols (Pacific Biosciences, CA). The library was size selected with the BluePippin system (Sage Science, MA), bound to polymerase using the DNA/polymerase binding kit P6v2, loaded onto 6 single-molecule real-time (SMRT) cells, and sequenced with C4v2 chemistry for 360-min movies on the RS II instrument (Pacific Biosciences, CA).
The reads (246,178 reads; mean read length, 12,377 bp) from the RS II instrument were filtered and de novo assembled using Canu version 1.6 (7) with default parameters. Non-Leishmania contigs identified using the NCBI-BLASTn algorithm were removed, and the remaining contigs were polished and corrected using unicycler_polish (Unicycler package version 4.4) (8) 
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